Nuvectra Corporation (NVTR) Issues Earnings Results

Nuvectra Corporation (NASDAQ:NVTR) announced its earnings results on Wednesday. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.07, reports. The firm had revenue of $7.60 million during the quarter, compared to analysts’ expectations of $8.08 million. Nuvectra Corporation had a negative return on equity of 56.68% and a negative net margin of 232.31%. The company’s revenue was up 100.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.92) earnings per share.

A number of brokerages have issued reports on NVTR. ValuEngine cut Nuvectra Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $14.00 target price on shares of Nuvectra Corporation in a research report on Thursday, July 6th. Finally, Zacks Investment Research raised Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $13.00.

In other Nuvectra Corporation news, CEO Scott F. Drees bought 10,000 shares of Nuvectra Corporation stock in a transaction dated Friday, August 11th. The stock was bought at an average cost of $11.72 per share, for a total transaction of $117,200.00. Following the purchase, the chief executive officer now owns 125,180 shares of the company’s stock, valued at approximately $1,467,109.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.60% of the company’s stock.

WARNING: “Nuvectra Corporation (NVTR) Issues Earnings Results” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

Nuvectra Corporation Company Profile

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Earnings History for Nuvectra Corporation (NASDAQ:NVTR)

What are top analysts saying about Nuvectra Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nuvectra Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit